Announcements
- Completion of the combination between Novozymes and Chr. Hansen
- All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
- Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted
- Major shareholder announcement from Burlington Loan Management DAC
- Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained
- Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.
- Managers' Transaction
- Managers' Transactions
- Chr. Hansen Holding A/S Interim Report Q4 2022/23
- Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1,860.86 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | -- |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Nov 24 2022 |
Div pay-date | Nov 28 2022 |
Data delayed at least 20 minutes, as of May 06 2021 12:30 BST.
More ▼